Therapeutic Play Kit
Find information on
GAMMAGARD Therapy
Find detailedGAMMAGARD therapy
offers 3 IVIG options
GAMMAGARD therapy offers 3 IVIG options
GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] 10%
GAMMAGARD LIQUID therapy is the first 10% IVIG solution with the unique combination of these four features1:
- No added sugars
- No added sodium
- No added preservatives
- Latex-free packaging
Learn more about GAMMAGARD Options
GAMMAGARD S/D [Immune Globulin Intravenous (Human)]
GAMMAGARD S/D therapy is a highly effective and purified therapy for immune compromised patients. GAMMAGARD S/D therapy is indicated for use in patients with:
- Primary Immune Deficiency diseases (PI)
- B-cell chronic lymphocytic leukemia (CLL)
- Idiopathic thrombocytopenic purpura (ITP)
- Kawasaki syndrome
GAMMAGARD S/D is indicated for the treatment of primary immunodeficient states, such as: congenital agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
GAMMAGARD S/D is not indicated in patients with selective IgA deficiency where the IgA deficiency is the only abnormality of concern. See Warnings section of full Prescribing Information for important risk information.
GAMMAGARD S/D [Immune Globulin Intravenous (Human)], IgA less than 1 µg/mL in a 5% solution
For your patients who require a Low IgA IVIG therapy, Baxter offers GAMMAGARD S/D therapy with IgA less than 1 µg/mL in a 5% solution.
GAMMAGARD S/D therapy with IgA less than 1 µg/mL in a 5% solution must not be used in patients with selective IgA deficiency where the deficiency is the only abnormality of concern.
- Available in both 5g and 10g sizes
- Unique product codes to simplify ordering
- IgA less than 1 µg/mL in a 5% solution
- No clinical studies have been specifically conducted using only lots whose IgA content was less than 1 µg/mL.
- IVIG preparations depleted of IgA (0.4 to 2.9 µg/mL) were shown to be better tolerated by a limited number of patients who reacted to IVIG preparations with higher IgA concentrations. However, the concentration of IgA that will not provoke a reaction is not known, and therefore all IVIG preparations carry the risk of inducing an anaphylactic reaction to IgA.
GAMMAGARD Therapies Comparison Chart
| GAMMAGARD S/D [Immune Globulin Intravenous (Human)] |
GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] 10%1 | |
| Form | Lyophilized2 | Liquid |
| Gammaglobulin (IgG) | ≥90%2 | ≥98% |
| Sodium content | 8.5 mg/mL | None detectable |
| Sugar content | 2% glucose2* | No added sugars |
| Osmolality | 1250 mOsmol/kg3 (10%) 636 mOsmol/kg3 (5%) |
240-300 mOsmol/kg |
| Shelf life | 24 months3 | 3 years refrigerated (2°-8° C [36° - 46° F]) or 9 months room temperature (25° C[77°F]) within 24 months of the date of processing |
| Reconstitution time | 5 min. (> 20 min. if cold)3 | None (ready to use) |
| Administration | Filter required2 | In-line filter optional |
| Dosing sizes | 4 (0.5,2.5,5,10 g)2 | 5 (1,2.5,5,10,20 g) |
| pH | 6.8±0.4 (reconstituted)2 | 4.6-5.1 |
| Viral inactivation/removal steps | Solvent/detergent treatment2 | 3 dedicated steps • Solvent/detergent treatment • 35nm Nanofiltration • Low pH incubation |
| Latex content | Packaging contains latex2 | Latex-free packaging |
* Data was calculated based on reconstitution to 10%.
GAMMAGARD LIQUID is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
Please see the detailed Important Risk Information and Full Prescribing Information for GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] for full prescribing details.
GAMMAGARD S/D and GAMMAGARD S/D, IgA less than 1 µg/mL in a 5% solution are indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies. GAMMAGARD S/D must not be used in patients with selective IgA deficiency (IgA < 0.05 g/L) where the IgA deficiency is the only abnormality of concern.
Please see the detailed Important Risk Information and Full Prescribing Information for GAMMAGARD S/D [Immune Globulin Intravenous (Human)] for full prescribing details.
Please see the detailed Important Risk Information and Full Prescribing Information for GAMMAGARD S/D [Immune Globulin Intravenous (Human)], IgA less than 1 µg/mL in a 5% solution for full prescribing details.
- GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] 10% package insert. Westlake Village, CA. Baxter International Inc.; October 2009.
- GAMMAGARD S/D [Immune Globulin Intravenous (Human)] 10% package insert. Westlake Village, CA. Baxter International Inc.; December 2009.
- Siegel J. Intravenous immune globulins: Therapeutic, pharmaceutical, and cost considerations. Pharmacy Practice News. January 2004;23.
